Research map: Matching‐Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second‐Line Myelofibrosis Therapy

Back to the article

Papers in this map

  1. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis · Srđan Verstovšek · 2012 · 2107 citations · Cited by this paper
  2. Low‐Dose Chidamide Maintenance Therapy After Hematopoietic Stem Cell Transplantation for T‐Cell Acute Lymphoblastic Leukemia: A Case Series · 2026 · Related
  3. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis · Claire N. Harrison · 2012 · 1833 citations · Cited by this paper
  4. Decoding the Heterogeneity of Diffuse Large B‐Cell Lymphomas: A Comprehensive Genetic, Transcriptomic, and Phenotypic Profiling of B‐Cell Lymphoma Cell Lines · 2026 · Related
  5. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis · Animesh Dev Pardanani · 2015 · 487 citations · Cited by this paper
  6. Sequential BV‐AVD Therapy in Richter Transformation: Insights Into the Management of Elderly Patients · 2026 · Related
  7. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis · John O Mascarenhas · 2018 · 399 citations · Cited by this paper
  8. Nucleoporin 98 Rearrangements in Acute Leukemia: A Genomic Landscape Study · 2026 · Related
  9. Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management · Ayalew Tefferi · 2023 · 304 citations · Cited by this paper
  10. Trends in Incidence and Survival of Patients With Primary Effusion Lymphoma in the United States: A Population Based Cohort Study · 2026 · Related
  11. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis · Aaron Thomas Gerds · 2020 · 94 citations · Cited by this paper
  12. Real‐World Treatment Patterns and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States · 2026 · Related
  13. Momelotinib treatment‐emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis · Ramy A. Abdelrahman · 2014 · 72 citations · Cited by this paper
  14. Integrative Transcriptomic and Functional Analysis of PKMYT1 Reveals a Potential Therapeutic Target in Chronic Lymphocytic Leukemia · 2026 · Related
  15. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis · Ayalew Tefferi · 2023 · 63 citations · Cited by this paper
  16. Clinical Significance of FLT3‐ITD Variation Allele Frequency in Acute Myeloid Leukemia: A Multicenter Study · 2026 · Related
  17. A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management · Benjamin Garmezy · 2020 · 58 citations · Cited by this paper
  18. Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T‐Cell Infusion: A Case Report With Mechanistic Insight · 2026 · Related
  19. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials · Srđan Verstovšek · 2023 · 55 citations · Cited by this paper
  20. Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study · 2026 · Related
  21. ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis · Andrea Duminuco · 2023 · 35 citations · Cited by this paper
  22. Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single‐arm, open‐label, phase 2, multicenter study · Yi Zhang · 2023 · 24 citations · Cited by this paper
  23. Jaktinib ( JAK1 /2 inhibitor): A momelotinib derivative with similar activity and optimized dosing schedule · Ayalew Tefferi · 2022 · 16 citations · Cited by this paper
  24. Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single‐arm , open‐label , phase 2, multicenter study · Yi Zhang · 2023 · 12 citations · Cited by this paper
  25. Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis · Vikas K Gupta · 2023 · 12 citations · Cited by this paper
  26. Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis · Lucia Masárová · 2025 · 8 citations · Cited by this paper
  27. Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis · Lucia Masárová · 2025 · 6 citations · Cited by this paper
  28. Jaktinib and momelotinib for the treatment of myelofibrosis—Birds of a feather? · Ayalew Tefferi · 2023 · 3 citations · Cited by this paper
  29. Predictors of response to pacritinib therapy and survival among 60 Mayo Clinic patients with myelofibrosis treated outside of clinical trials · Maymona G. Abdelmagid · 2025 · 3 citations · Cited by this paper
  30. Poster Sessions · Lukas Haaksma, · 2025 · 3 citations · Cited by this paper
  31. Untitled · Cited by this paper

Source: OpenAlex (CC0)